Biotricity Expands IP Portfolio With More Than a Dozen New Patents

Biotricity Inc. has bolstered its intellectual property (IP) prowess with 14 new patents focusing on remote patient monitoring technology.

The patent influx brings the company’s total to 15 issued patents, with an additional 14 pending. The expansion of the company’s IP portfolio underscores Biotricity’s mission to advance and improve patient care. By streamlining diagnostic processes, Biotricity helps medical providers detect potential health issues earlier, improving patient outcomes while also reducing the burden on the stressed healthcare system.

“At Biotricity, we believe that the future of patient care lies in the ability to monitor and manage individuals from the comfort of their home,” Biotricity Founder/CEO Dr. Waqaas Al-Siddiq said. “Our solutions deliver actionable data to healthcare providers, facilitating quicker intervention to improve patient outcomes while driving revenue through insurance reimbursement.”

Biotricity’s newest group of patents represents a breakthrough in remote patient monitoring technology, with a focus on multi-sensor patch devices capable of collecting various biometrics. These innovations are centered on a versatile device platform with base components that can be inserted into a patch form factor, then removed and placed into a watch form factor. This adaptable design ensures wider integration and compliance for different patient needs and clinical applications.

This group of patents will drive Biotricity’s next-generation device, which could enable multiple diagnostic studies to be conducted simultaneously. For instance, patients needing a cardiac and sleep study would traditionally have to navigate fragmented care pathways, schedule multiple appointments, and endure long wait times. With Biotricity, these critical diagnostic assessments could be performed concurrently with the same device, reducing delays in diagnosis and expediting treatment.

“As part of our R&D strategy, we continue to mindfully develop a diversified IP portfolio that integrates patents, trade secrets, FDA clearances, and trademarks, while ensuring each product or technology is aligned with reimbursement and clinical outcomes,” Al-Siddiq stated. “We expect to secure further patents this year and next. By expanding our IP portfolio, we are not only reinforcing our leadership in the industry but also ensuring that our technology remains at the forefront of innovation.”

Biotricity strives to bridge the gap in remote monitoring and chronic care management. The company develops comprehensive remote health monitoring solutions for the medical and consumer markets.